Who are the mHSPC patients for triplet therapy after #GU23? Clinical and some pathological factors can help. Biomarkers are urgent. Could SPOP status help? @OncologyBio meeting @DrAndreFay #leonardoatem #karinetrindade

Controversies about therapies in mUC after #GU23. How many patients receive 1, 2 and 3L therapy? Do we need check FGFR for all? When? 3 or 6 cycles of chemo? Platinum eligibility. Cisplatin fit patients should receive cisplatin or carboplatin is acceptable? @OncologyBio meeting

Discussion about one of the best studies from #GU23. The importance of biomarkers to define who will or will not have benefit of chemotherapy in patients with CSI testicular cancer @OncologyBio meeting @asasse

Is it time to triplet therapy for #RCC after #GU23? Maybe too early to detect who will benefit for this strategy @OncologyBio meeting @FabioSchutz78 @adrigons

Amazing interactive discussion with the audience about the use of cisplatin or carboplatin after update of JAVELIN Bladder in the #GU23 @OncologyBio meeting @DanielVargas_ @fsabino_onco @FabioSchutz78 @DrAndreFay @asasse #karinetrindade

We are on line. Great debate in urothelial carcinoma and how to apply the evidences after #GU23 @OncologyBio @DanielVargas_ @fsabino_onco

Starting now the post #GU23 discussion with @DrAndreFay @OncologyBio

Outstanding discussion about the best studies from #GU23 in a @OncologyBio meeting @DanielVargas_ @fsabino_onco

Amazing data. Should bi-parametric MRI, radiomics and AI increase the detection rate of clinical significant PC in a faster and hopefully cheaper way? #GU23 @ASCO @OncologyBio

Cabopoint and BIONIKK are interesting studies to help decisions for a 2 line therapy in #RCC while we’re still waiting for phase 3 trials for patients progressing after 1L IO based. #GU23 @ASCO @OncologyBio

Starting #GU23 with an outstanding review about 1L treatment of #RCC and an interesting spoiller about what we’ll see at #GU23 about #RCC with @BourlonMaite during a @OncologyBio meeting

It still intriguing the positivity data from the non-HRR patients. Another important point is how these data are important for patients receiving a NHT in the mCSPC setting #GU23 @OncologyBio

Interesting data, but how many patients were PSA persistent (RTOG) and how many relapse after 6 months (GETUG-16)? Radical-HD has a mixture of them. How PSMA PET would change the stage in a high risk population? #GU23 @OncologyBio

A very important and practical question is: does have any patient who failed to ADT plus NHT in mHSPC that deserve PARPi combinations in the mCRPC scenario? #GU23 @OncologyBio

Interesting OS curve from PROPEL with a separation after 22 months, coincident with the rPFS. Is the post-progression therapy influencing this data? #GU23 @OncologyBio